- Home
- UYSCU vs PTCT Comparison
UYSCU vs PTCT Comparison
Compare UYSCU & PTCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UYSCU
- PTCT
- Stock Information
- Founded
- UYSCU N/A
- PTCT 1998
- Country
- UYSCU
- PTCT United States
- Employees
- UYSCU N/A
- PTCT N/A
- Industry
- UYSCU
- PTCT Biotechnology: Pharmaceutical Preparations
- Sector
- UYSCU
- PTCT Health Care
- Exchange
- UYSCU NYSE
- PTCT Nasdaq
- Market Cap
- UYSCU N/A
- PTCT 3.7B
- IPO Year
- UYSCU N/A
- PTCT 2013
- Fundamental
- Price
- UYSCU $10.17
- PTCT $48.52
- Analyst Decision
- UYSCU
- PTCT Buy
- Analyst Count
- UYSCU 0
- PTCT 13
- Target Price
- UYSCU N/A
- PTCT $62.31
- AVG Volume (30 Days)
- UYSCU N/A
- PTCT 1.6M
- Earning Date
- UYSCU N/A
- PTCT 05-06-2025
- Dividend Yield
- UYSCU N/A
- PTCT N/A
- EPS Growth
- UYSCU N/A
- PTCT N/A
- EPS
- UYSCU N/A
- PTCT 7.51
- Revenue
- UYSCU N/A
- PTCT $1,772,758,000.00
- Revenue This Year
- UYSCU N/A
- PTCT $99.06
- Revenue Next Year
- UYSCU N/A
- PTCT N/A
- P/E Ratio
- UYSCU N/A
- PTCT $6.46
- Revenue Growth
- UYSCU N/A
- PTCT 91.12
- 52 Week Low
- UYSCU N/A
- PTCT $28.72
- 52 Week High
- UYSCU N/A
- PTCT $58.38
- Technical
- Relative Strength Index (RSI)
- UYSCU N/A
- PTCT 55.25
- Support Level
- UYSCU N/A
- PTCT $44.54
- Resistance Level
- UYSCU N/A
- PTCT $49.15
- Average True Range (ATR)
- UYSCU 0.00
- PTCT 1.72
- MACD
- UYSCU 0.00
- PTCT 0.48
- Stochastic Oscillator
- UYSCU 0.00
- PTCT 87.67
About UYSCU UY SCUTI ACQUISITION CORP UNIT 1 ORD & 1 RT
UY Scuti Acquisition Corp is a newly organized blank check company.
About PTCT PTC Therapeutics Inc.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The Company views its operations and manages its business in one operating segment: life science.